Marco Taglietti's Insider Trades & SAST Disclosures
Marco Taglietti's most recent trade in Aquestive Therapeutics Inc was a trade of 38,000 Stock Option (Right to Purchase) done . Disclosure was reported to the exchange on June 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Marco Taglietti.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | Marco Taglietti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Purchase) | |
| Aquestive Therapeutics Inc | Marco Taglietti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Purchase) | |
| Aquestive Therapeutics Inc | Marco Taglietti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Purchase) | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 26 Apr 2022 | 75,000 | 272,068 (0%) | 0% | 3 | 225,000 | Common Stock |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 75,000 | 75,000 | - | - | Common Stock Warrant | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 232,000 | 232,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 87,200 | 196,968 (0%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Marco Taglietti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Purchase) | |
| Aquestive Therapeutics Inc | Marco Taglietti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 28,500 | 28,500 | - | - | Non-Qualified Stock Option (right to buy) | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.25 per share. | 21 Dec 2020 | 40,000 | 109,668 (0%) | 0% | 6.3 | 250,000 | Common Stock |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 20,000 | 20,000 | - | - | Common Stock Warrant | |
| Scynexis Inc | Marco Taglietti | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 20,000 | 20,000 | - | - | Common Stock Warrant |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges